February newsletter in 60 seconds
19-02-2015
Think of the word ‘counterfeit’ and your mind is likely to conjure up images of poorly made electronic goods, branded merchandise missing a letter or two, or market traders selling goods whose prices seem too good to be true.
But what about death? Yes, unfortunate as it is, there can be a strong link between fake medicine and the loss of life, which is clearly why counterfeit pharmaceutical products must be combated more quickly and comprehensively than other fakes.
Aided by the internet, the sale and distribution of rogue pills and treatments has become not only more widespread, but more difficult to eradicate. Authorities such as the World Customs Organization (WCO) are doing an impressive job of trying to clean up the market (as you will read in this issue), but the scale of the challenge facing them is huge.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
